Liang Dong1,2, Yun Su3, Yinjie Zhu2, Mark C Markowski4, Mei Xin5, Michael A Gorin1, Baijun Dong2, Jiahua Pan2, Martin G Pomper6, Jianjun Liu5, Kenneth J Pienta1, Wei Xue7, Steven P Rowe8. 1. James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 4. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; and. 6. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; srowe8@jhmi.edu uroxuewei@163.com. 8. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland srowe8@jhmi.edu uroxuewei@163.com.
Abstract
Our purpose was to evaluate the association of a new biochemical recurrence (BCR) risk stratification system with PSMA-targeted PET/CT findings. Methods: Two prospective studies that included patients with BCR were pooled. Findings on PSMA PET were catalogued. Patients were characterized according to the European Association of Urology BCR risk categories. Univariable and multivariable analyses were performed by logistic regression. Results: In total, 145 patients were included (45 low-risk and 100 high-risk). High-risk BCR patients had a higher positive rate than low-risk patients (82.0% vs. 48.9%; P < 0.001) and reached independent predictor status for positive PSMA PET/CT scan results on multivariable logistic regression (odds ratio, 6.73; 95% CI, 2.41-18.76; P < 0.001). The area under the curve using the combination of BCR risk group and prostate-specific antigen was higher than that using prostate-specific antigen alone (0.834 vs. 0.759, P = 0.015). Conclusion: The European Association of Urology BCR risk groups define the candidates who can most benefit from a PSMA PET/CT scan when BCR occurs.
Our purpose was to evaluate the association of a new biochemical recurrence (BCR) risk stratification system with PSMA-targeted PET/CT findings. Methods: Two prospective studies that included patients with BCR were pooled. Findings on PSMA PET were catalogued. Patients were characterized according to the European Association of Urology BCR risk categories. Univariable and multivariable analyses were performed by logistic regression. Results: In total, 145 patients were included (45 low-risk and 100 high-risk). High-risk BCR patients had a higher positive rate than low-risk patients (82.0% vs. 48.9%; P < 0.001) and reached independent predictor status for positive PSMA PET/CT scan results on multivariable logistic regression (odds ratio, 6.73; 95% CI, 2.41-18.76; P < 0.001). The area under the curve using the combination of BCR risk group and prostate-specific antigen was higher than that using prostate-specific antigen alone (0.834 vs. 0.759, P = 0.015). Conclusion: The European Association of Urology BCR risk groups define the candidates who can most benefit from a PSMA PET/CT scan when BCR occurs.
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Marlon Perera; Nathan Papa; Matthew Roberts; Michael Williams; Cristian Udovicich; Ian Vela; Daniel Christidis; Damien Bolton; Michael S Hofman; Nathan Lawrentschuk; Declan G Murphy Journal: Eur Urol Date: 2019-02-14 Impact factor: 20.096
Authors: Michael A Gorin; Steven P Rowe; Mark C Markowski; Ramy Sedhom; Wei Fu; Javaughn Corey R Gray; Mario A Eisenberger; Martin G Pomper; Kenneth J Pienta Journal: J Urol Date: 2020-04-06 Impact factor: 7.450
Authors: Thomas Van den Broeck; Roderick C N van den Bergh; Erik Briers; Philip Cornford; Marcus Cumberbatch; Derya Tilki; Maria De Santis; Stefano Fanti; Nicola Fossati; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Michael Lardas; Matthew Liew; Malcolm Mason; Lisa Moris; Ivo G Schoots; Theodorus van der Kwast; Henk van der Poel; Thomas Wiegel; Peter-Paul M Willemse; Olivier Rouvière; Thomas B Lam; Nicolas Mottet Journal: Eur Urol Focus Date: 2019-06-24
Authors: Misop Han; Alan W Partin; Marianna Zahurak; Steven Piantadosi; Johnathan I Epstein; Patrick C Walsh Journal: J Urol Date: 2003-02 Impact factor: 7.450
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Justin Ferdinandus; Wolfgang P Fendler; Andrea Farolfi; Samuel Washington; Osama Mohamad; Miguel H Pampaloni; Peter J H Scott; Melissa Rodnick; Benjamin L Viglianti; Matthias Eiber; Ken Herrmann; Johannes Czernin; Wesley R Armstrong; Jeremie Calais; Thomas A Hope; Morand Piert Journal: J Nucl Med Date: 2021-10-07 Impact factor: 11.082